Sign up Australia
Proactive Investors - Run By Investors For Investors

Zelda Therapeutics approved for Australia’s first medicinal cannabis trial targeting insomnia

Patient recruitment for the clinical trial is expected to commence shortly.
Zelda Therapeutics approved for Australia’s first medicinal cannabis trial targeting insomnia
Zelda shares are trading five-times higher than a year ago

Zelda Therapeutics Ltd's (ASX:ZLD) shares have bounded 13% higher to $0.13 in early trade following the company being approved for Australia’s first medicinal cannabis trial for insomnia.

The clinical trial approval was granted from the Therapeutics Goods Administration and the Human Research Ethics Committee.

The trial will be undertaken by the prestigious University of Western Australia (UWA) Centre for Sleep Science (CSS), which has state of the art research facilities and is directed by Professor Peter Eastwood, National Health and Medical Research Council Senior Research Fellow.

Zelda’s clinical trial will target a sample population of people with characteristic symptoms of chronic insomnia, which include difficulty falling and staying asleep on a long-term basis.

A randomised, placebo controlled, cross over study design will be used, where patients are selected at random to be treated with Zelda’s medicinal cannabis formulation or a placebo formulation.

Harry Karelis, executive chairman for Zelda, commented: "This is a very exciting milestone for Zelda.

"We have been meticulously working our way through the regulatory framework to ensure we achieve all necessary approvals.

"This has been a very rigorous process and has taken some time but we are now very well positioned and are the first to undertake a clinical trial of this nature in Australia.

"We are very pleased to have partnered with the leading researchers in this field at the prestigious UWA Centre for Sleep Science, and are confident this clinical trial will deliver the high-quality data we need to further develop and commercialise our medicinal cannabis formulation."

WATCH: Zelda's Stewart Washer discussed medical cannabis trials with investors at Proactive's CEO Sessions

The company has been focused on targeting its medicinal cannabis formulations to treat a number of disease conditions, and progress its research to clinical trials, the first being chronic insomnia.

Professor Peter Eastwood, director, centre for sleep science, added:

"Australia has been a leader in sleep medicine for many years and our Western Australia based Centre comes equipped with state-of-the-art sleep recording and analysis equipment.

"For this trial we have assembled a team of experts including sleep physiologists, sleep physicians and clinical psychologists."

Patient data

Zelda has access to patient data in the U.S. and Chile, which shows anecdotal evidence of benefit from medicinal cannabis when used to treat insomnia.

Based on this data and other studies on the safety of medicinal cannabis, the company has worked with the research team at UWA to develop a rigorous research trial protocol to study the clinical efficacy of its insomnia formulations.

Analysis

It is anticipated that the clinical trial will formally commence in the first quarter of 2018, with patient recruitment expected to commence shortly.

Clinical trials are a key research tool for advancing medical knowledge and patient care.

Population-based data show that about one third of adults have regular difficulty getting to sleep or staying asleep.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

medical cannabis
October 01 2018
The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile.
Woman holding cannabis leaf
October 16 2018
Canadian subsidiary Crystal Mountain is expanding its range of hydroponics equipment to meet expected demand.
1539364967_Cannabis-plant.jpg
October 10 2018
Management behind ICC International Cannabis Corp has a clear buy, build and sell strategy

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use